Multicenter trial of naloxone in alzheimer's disease

V. W. Henderson, E. Roberts, C. Wimer, E. L. Bardolph, H. C. Chui, A. R. Damasio, P. J. Eslinger, M. F. Folstein, L. S. Schneider, E. L. Teng, L. E. Tune, L. P. Weiner, P. J. Whitehouse

Research output: Contribution to journalArticlepeer-review

Abstract

In a double‐blind, placebo‐controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1‐mg or 10‐mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)404-406
Number of pages3
JournalAnnals of neurology
Volume25
Issue number4
DOIs
StatePublished - Apr 1989
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Multicenter trial of naloxone in alzheimer's disease'. Together they form a unique fingerprint.

Cite this